Sutro Biopharma, Inc. and Blackstone announced the companies have entered into a royalty financing collaboration agreement where funds managed by Blackstone Life Sciences will provide $140 million upfront, with up to an additional $250 million in future milestone payments triggered at various return thresholds, in exchange for Sutroâs 4% royalty, or revenue interest, in the potential future sales of Vaxcyteâs products, including VAX-24 and other products that Vaxcyte develops under its license with Sutro. Vaxcyteâs lead candidate, VAX-24, is a Phase 3 ready, 24-valent next-generation pneumococcal conjugate vaccine (PCV) with enhanced serotype coverage and immunogenicity. Vaxcyteâs PCV franchise is enabled by Sutroâs XpressCF® cell-free protein synthesis technology.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
122.5 USD | -0.03% | +3.45% | -6.44% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
122.5 USD | -0.03% | +3.45% | 88.47B | ||
3.42 USD | 0.00% | -5.79% | 263M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.44% | 88.47B | |
+15.32% | 84.55B | |
+12.36% | 26.01B | |
-6.65% | 17.28B | |
+6.74% | 14.28B | |
-16.11% | 13.16B | |
+16.00% | 9.52B | |
+26.11% | 8.75B | |
+27.22% | 7.13B | |
+7.48% | 5.32B |
- Stock Market
- Equities
- BX Stock
- News Blackstone Inc.
- Sutro Biopharma and Blackstone Announces Royalty Financing Collaboration